A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women

INTRODUCTION: Despite a decrease in infections caused by Bordetella pertussis due to COVID-19 pandemic, booster vaccination of pregnant women is still recommended to protect newborns. Highly immunogenic vaccines containing genetically inactivated pertussis toxin (PT(gen)) and filamentous hemagglutin...

Descripción completa

Detalles Bibliográficos
Autores principales: Puthanakit, Thanyawee, Chokephaibulkit, Kulkanya, Chaithongwongwatthana, Surasith, Bhat, Niranjan, Tang, Yuxiao, Anugulruengkitt, Suvaporn, Chayachinda, Chenchit, Anuwutnavin, Sanitra, Lapphra, Keswadee, Rungmaitree, Supattra, Tawan, Monta, Andi-Lolo, Indah, Holt, Renee, Fortuna, Librada, Kerdsomboon, Chawanee, Yuwaree, Vilasinee, Mansouri, Souad, Thai, Pham Hong, Innis, Bruce L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier Science 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267846/
https://www.ncbi.nlm.nih.gov/pubmed/37330371
http://dx.doi.org/10.1016/j.vaccine.2023.06.001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10267846/
https://www.ncbi.nlm.nih.gov/pubmed/37330371
http://dx.doi.org/10.1016/j.vaccine.2023.06.001

Ejemplares similares